NCT02523040: Lenalidomide for Adult Histiocyte Disorders
- State
- Under way
- Phase
- Phase 2
- People
- 12 taking part
- Started
- Aug 2015
- Primary completion
- Feb 2024
- Arms
- Lenalidomide
- Results
- Posted on the registry
- 14 Aug 2015: Trial registered
- 25 Apr 2025: Trial results posted
Posted results
The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.
Overall Response Rate (ORR)
Primary outcome · Number, proportion of participants · Disease assessed every 3 cycles on treatment up do 12 cycles (approximately 12 months).
| Group | Analysed | Value |
|---|---|---|
| Lenalidomide | 12 | 0.67 (90% Confidence Interval 0.39 to 0.88) |
12-months Progression-free Survival (PFS)
Secondary outcome · Number, percentage probability · Disease assessed on treatment every 3 cycles and in long-term follow-up up to the earlier of 36 months (every 3 months for 2 years then every 6 months) or start of new anti-cancer therapy. Relevant for this endpoint was12-months estimate.
| Group | Analysed | Value |
|---|---|---|
| Lenalidomide | 12 | 62 (95% Confidence Interval 39 to 100) |
12-months Overall Survival (OS)
Secondary outcome · Number, percentage probability · 12 Months
| Group | Analysed | Value |
|---|---|---|
| Lenalidomide | 12 | 92 (95% Confidence Interval 77 to 100) |
Incidence of Grade 3-4 Toxicity
Secondary outcome · Number, proportion of participants · Up to 12 months on treatment.
| Group | Analysed | Value |
|---|---|---|
| Lenalidomide | 12 | 0.25 (90% Confidence Interval 0.07 to 0.53) |
Percent Change in Serum TNF-alpha Levels on Therapy From Baseline up to 12 Cycles
Secondary outcome · Median, percent change from baseline · Measured at baseline, day 1 of cycles 3, 6 ad 12 cycles and within 28 days post-treatment end (up to 13 months).
| Group | Analysed | Value |
|---|---|---|
| Lenalidomide | 6 | -14.4 (Full Range -67.3 to 8.3) |